The Centers for Medicare & Medicaid Services granted coverage for Personalis’s NeXT Personal molecular residual disease (MRD) test for surveillance of stages I–III non‑small cell lung cancer. CMS based the determination on performance data generated in partnership with the TRACERx consortium and published validation work. Personalis said the decision widens patient access to whole‑genome–based MRD surveillance and is expected to accelerate commercial uptake and partnerships for recurrence monitoring. The coverage decision follows earlier Medicare coverage for breast‑cancer MRD surveillance and positions whole‑genome and tumor‑informed assays to play a larger role in post‑treatment monitoring and earlier intervention strategies.